Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pegipanermin · INB-03, XPro1595

Recombinant protein · Inhibitor of Soluble tumor necrosis factor (TNF-alpha) (TNF) · developed by Inmune Bio

Phase 2/3 Most advanced trial (none active)
INMB Developer
2 Registered trials

What is Pegipanermin?

Pegipanermin is a pegylated, engineered dominant-negative TNF-alpha variant lacking TNF receptor-binding activity. It forms heterotrimers with soluble TNF, preventing it from binding TNF receptors and reducing pro-inflammatory signaling. It is being studied in COVID-19 and in Alzheimer disease and related dementias.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INB-03, XPro1595, XENP-1595, DN-TNF, XPro1595, XENP345, Quellor, DN-TNF
Drug type
Recombinant protein
Targets
Soluble tumor necrosis factor (TNF-alpha) (TNF), TNF receptor 1 (TNFR1) (TNFRSF1A) (binding partner it blocks)
Mechanism
Inhibitor of Soluble tumor necrosis factor (TNF-alpha) (TNF)
Pathways
TNFR1 pro-inflammatory signaling
Therapy area
Infectious disease, Neurology
Developer
Inmune Bio, Inc. (INMB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
BM6T2K8FIN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04370236 Phase 2/3 COVID-19 Terminated INMB
NCT05318976 Phase 2 Alzheimer Disease Completed INMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesCOVID-19DementiaMental DisordersMild Cognitive ImpairmentNervous System DiseasesNeurocognitive DisordersNeurodegenerative DiseasesTauopathies

Other drugs acting on TNF

More from Inmune Bio

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INMB page.

Follow INMB, the company behind Pegipanermin

See INMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INMB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.